CERA

unofficial impact factor 1.46
Search for
Advanced search
Cost Effectiveness and Resource Allocation
Tools
Open Access Email this article to a friend

Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration

Susan F Hurley*, Jane P Matthews and Robyn H Guymer

Cost Effectiveness and Resource Allocation 2008, 6:12 doi:10.1186/1478-7547-6-12

Fields marked * are required


Multiple email addresses should be separated with commas or semicolons.